Form 4 for FDMT 4D Molecular Therapeutics, Inc.
Accepted 2023-06-06 00:00:00 ET · period of report 2023-06-01 · accession 0001610717-23-000098 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-06 | 2023-06-01 | FDMT | Bizily Scott | Chief Legal, HR Off | S - Sale+OE | $18.31 | -2,247 | 1,737 | -56% | -$41.1K |
| D | 2023-06-06 | 2023-06-01 | FDMT | Bizily Scott | Chief Legal, HR Off | M - OptEx | $6.49 | +1,875 | 3,984 | +89% | +$12.2K |
| D | 2023-06-06 | 2023-06-01 | FDMT | Bizily Scott | Chief Legal, HR Off | M - OptEx | $0.00 | -1,875 | 18.4K | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-01 | S | D | 2,247 | $18.31 | 1,737 | D | — | — | (F2) The transaction was executed in multiple trades in prices ranging from $17.95 to $18.69, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2023-06-01 | M | A | 1,875 | $6.49 | 3,984 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-06-01 | M | D | 1,875 | $0.00 | 18,375 | D | $6.49 · — to 2032-06-17 | 1,875 Common Stock | (F3) The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |